204 related articles for article (PubMed ID: 29737795)
1. The anti-wasting effects of L-carnitine supplementation on cancer: experimental data and clinical studies.
Esfahani M; Sahafi S; Derakhshandeh A; Moghaddas A
Asia Pac J Clin Nutr; 2018; 27(3):503-511. PubMed ID: 29737795
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms underlying the anti-wasting effect of L-carnitine supplementation under pathologic conditions: evidence from experimental and clinical studies.
Ringseis R; Keller J; Eder K
Eur J Nutr; 2013 Aug; 52(5):1421-42. PubMed ID: 23508457
[TBL] [Abstract][Full Text] [Related]
3. L-Carnitine: an adequate supplement for a multi-targeted anti-wasting therapy in cancer.
Busquets S; Serpe R; Toledo M; Betancourt A; Marmonti E; Orpí M; Pin F; Capdevila E; Madeddu C; López-Soriano FJ; Mantovani G; Macciò A; Argilés JM
Clin Nutr; 2012 Dec; 31(6):889-95. PubMed ID: 22608917
[TBL] [Abstract][Full Text] [Related]
4. L-carnitine ameliorates cancer cachexia in mice by regulating the expression and activity of carnitine palmityl transferase.
Liu S; Wu HJ; Zhang ZQ; Chen Q; Liu B; Wu JP; Zhu L
Cancer Biol Ther; 2011 Jul; 12(2):125-30. PubMed ID: 21532335
[TBL] [Abstract][Full Text] [Related]
5. Advances in pharmacologic strategies for cancer cachexia.
Madeddu C; Mantovani G; Gramignano G; Macciò A
Expert Opin Pharmacother; 2015; 16(14):2163-77. PubMed ID: 26330024
[TBL] [Abstract][Full Text] [Related]
6. The role of vitamin D in cancer cachexia.
Penna F; Camperi A; Muscaritoli M; Filigheddu N; Costelli P
Curr Opin Support Palliat Care; 2017 Dec; 11(4):287-292. PubMed ID: 28922293
[TBL] [Abstract][Full Text] [Related]
7. L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN)--a randomized multicentre trial.
Kraft M; Kraft K; Gärtner S; Mayerle J; Simon P; Weber E; Schütte K; Stieler J; Koula-Jenik H; Holzhauer P; Gröber U; Engel G; Müller C; Feng YS; Aghdassi A; Nitsche C; Malfertheiner P; Patrzyk M; Kohlmann T; Lerch MM
Nutr J; 2012 Jul; 11():52. PubMed ID: 22824168
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase III clinical trial of five different arms of treatment for patients with cancer cachexia: interim results.
Mantovani G; Macciò A; Madeddu C; Gramignano G; Serpe R; Massa E; Dessì M; Tanca FM; Sanna E; Deiana L; Panzone F; Contu P; Floris C
Nutrition; 2008 Apr; 24(4):305-13. PubMed ID: 18262758
[TBL] [Abstract][Full Text] [Related]
9. Glycine administration attenuates skeletal muscle wasting in a mouse model of cancer cachexia.
Ham DJ; Murphy KT; Chee A; Lynch GS; Koopman R
Clin Nutr; 2014 Jun; 33(3):448-58. PubMed ID: 23835111
[TBL] [Abstract][Full Text] [Related]
10. Potential protective effects of l-carnitine against neuromuscular ischemia-reperfusion injury: From experimental data to potential clinical applications.
Moghaddas A; Dashti-Khavidaki S
Clin Nutr; 2016 Aug; 35(4):783-90. PubMed ID: 26199084
[TBL] [Abstract][Full Text] [Related]
11. Mitochondrial plasticity in cancer-related muscle wasting: potential approaches for its management.
Vitorino R; Moreira-Gonçalves D; Ferreira R
Curr Opin Clin Nutr Metab Care; 2015 May; 18(3):226-33. PubMed ID: 25783794
[TBL] [Abstract][Full Text] [Related]
12. Molecular Pathways: Cachexia Signaling-A Targeted Approach to Cancer Treatment.
Miyamoto Y; Hanna DL; Zhang W; Baba H; Lenz HJ
Clin Cancer Res; 2016 Aug; 22(16):3999-4004. PubMed ID: 27340276
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of skeletal muscle degradation and its therapy in cancer cachexia.
Melstrom LG; Melstrom KA; Ding XZ; Adrian TE
Histol Histopathol; 2007 Jul; 22(7):805-14. PubMed ID: 17455154
[TBL] [Abstract][Full Text] [Related]
14. L-Carnitine Ameliorates Cancer Cachexia in Mice Partly via the Carnitine Palmitoyltransferase-Associated PPAR-γ Signaling Pathway.
Jiang F; Zhang Z; Zhang Y; Pan X; Yu L; Liu S
Oncol Res Treat; 2015; 38(10):511-6. PubMed ID: 26452216
[TBL] [Abstract][Full Text] [Related]
15. l-carnitine and cancer cachexia: Clinical and experimental aspects.
Silvério R; Laviano A; Rossi Fanelli F; Seelaender M
J Cachexia Sarcopenia Muscle; 2011 Mar; 2(1):37-44. PubMed ID: 21475677
[TBL] [Abstract][Full Text] [Related]
16. Novel treatments for cancer cachexia.
Bossola M; Pacelli F; Doglietto GB
Expert Opin Investig Drugs; 2007 Aug; 16(8):1241-53. PubMed ID: 17685872
[TBL] [Abstract][Full Text] [Related]
17. L-carnitine and cancer cachexia. I. L-carnitine distribution and metabolic disorders in cancer cachexia.
Szefel J; Kruszewski WJ; Ciesielski M; Szajewski M; Kawecki K; Aleksandrowicz-Wrona E; Jankun J; Lysiak-Szydłowska W
Oncol Rep; 2012 Jul; 28(1):319-23. PubMed ID: 22562434
[TBL] [Abstract][Full Text] [Related]
18. Cancer cachexia: it's time for more clinical trials.
Bossola M; Pacelli F; Tortorelli A; Doglietto GB
Ann Surg Oncol; 2007 Feb; 14(2):276-85. PubMed ID: 17094025
[TBL] [Abstract][Full Text] [Related]
19. Reversal of cancer-related wasting using oral supplementation with a combination of beta-hydroxy-beta-methylbutyrate, arginine, and glutamine.
May PE; Barber A; D'Olimpio JT; Hourihane A; Abumrad NN
Am J Surg; 2002 Apr; 183(4):471-9. PubMed ID: 11975938
[TBL] [Abstract][Full Text] [Related]
20. Cancer cachexia.
Tisdale MJ
Langenbecks Arch Surg; 2004 Aug; 389(4):299-305. PubMed ID: 15168125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
